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SUMMARY
In recent years, the emergence of Plasmodium 
strains resistant to artemisinin derivatives, such as 
the commercial antimalarial Artesunate, has been 
detected. For this reason, in the search for new strat-
egies to malaria control, we used the antiplasmodial 
activity of natural products from plant Solanum nu-
dum, such as Tumacona B (SN2), to synthesize a new 
hybrid Artesunate-Tumacona B. The antiplasmodial 
activity and cytotoxicity of this hybrid was evaluated 
in vitro. We found a potent activity with IC50 = 0.0044 
µM in the strain 3D7 (chloroquine sensitive) and IC50 
= 0.0059 µM for the strain FCR3 (chloroquine resis-
tant) and low cytotoxicity in HepG2 human liver cells 
with a CC50 = 12.6 µM. This makes the hybrid a new 
and promising compound.
Keywords: Hybrid; antimalarial; sterols; artemisi-
nins; Plasmodium falciparum.
RESUMEN
Se ha detectado en los últimos años la aparición de 
cepas de Plasmodium resistentes a derivados de arte-
misininas como el antimalárico comercial Artesuna-
to, es por esto, que en la búsqueda de nuevas estra-
tegias para el control de la malaria se aprovechó la 
actividad antiplasmodial de productos naturales obte-
nidos de la planta Solanum nudum , como la Tumaco-
na B (SN2),  para sintetizar un nuevo híbrido Artesu-
nato–Tumacona B. A este híbrido se le evaluó in vitro 
su actividad antiplasmodial y citotoxicidad. Se encon-
tró una potente actividad con IC50 = 0.0044µM en la 
cepa 3D7 (Sensible a cloroquina) e IC50 = 0.0059µM 
para la cepa FCR3 (Resistente a cloroquina) y  baja ci-
totoxicidad en células hepáticas humanas HepG2 con 
CC50 =12.6µM  convirtiéndose en un nuevo y promi-
sorio compuesto.
Palabras clave: Híbrido; antimalárico; esteroles; ar-
temisininas; Plasmodium falciparum.
RESUM
S’ha detectat en els darrers anys l’aparició de soques 
de Plasmòdium resistents a derivats d’artemisinines 
com l’antimalàric comercial Artesunat, és per aquest 
a rao que a la recerca  de noves estrategias pel control 
de la malaria es va aprofitat l’activitat antiplasmodial 
de productes naturals obtinguts de la planta Solanum 
nudum, com la Tumacona B (SN2), per sintetitzar un 
nou híbrid Artesunat–Tumacona B. L’activitat anti-
plasmodial i la citotoxicitat d’aquest híbrid es va ava-
luar in vitro. Es va trovar una potent activitat amb IC50 
= 0.0044µM a la soca 3D7 (resistent a la cloroquina) i 
IC50 = 0.0059µM per a la soca FCR3 (resistent a la clo-
roquina) i baixa citotoxicitat en cèl.lules hepàtiques 
humanes HepG2 amb CC50 =12.6µM. Convertint l’hí-
brid en un nou i prometedor compost.
Paraules clau: Híbrid, antimalárico; esterols; arte-
misinina; Plasmòdium falciparum.
HIGHLIGHTS
• We synthesized a new hybrid Artesunate-Tu-
macona B with in vitro antiplasmodial activity 
in sensitive (3D7) and resistant (FCR3) P. falci-
parum strains.
• A new derivative of Tumacona B (SN2-YAM) 
with in vitro antiplasmodial activity in P. falci-
parum strains was obtained.
• The tested hybrid compounds were more ac-
tive than their corresponding combinations in 
chloroquine-sensitive (3D7) and chloroquine-
resistant (FCR3) strains of P. falciparum.
• The Artesunate-Tumacona B hybrid was 23.4 
times more active than chloroquine in a resis-
tant (FCR3) strain of P. falciparum.
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INTRODUCTION
Malaria is a potentially fatal disease caused by para-
sites of the genus Plasmodium, which are transmitted 
to humans by the bite of infected Anopheles mosqui-
toes. The species of Plasmodium that cause the larg-
est number of cases in the world are P. vivax and P. 
falciparum, the latter being the most deadly1. 
The World Health Organization estimates that there 
were about 214 million cases of the disease worldwide 
in 2015 that killed 438.000 people1. One of the rea-
sons of these figures is the difficulty in controlling 
the emergence and spread of strains of Plasmodium 
Spp resistant to antimalarial therapy. In the case of 
P. falciparum malaria, combined therapy based in 
artemisinin derivatives has been used in an attempt 
to overcome this obstacle. However, in recent years, 
resistance to this treatment option has been detected 
and resistance of P. falciparum to artemisinin-type 
drugs in regions such as Cambodia, Myanmar, Thai-
land and Vietnam, with great potential for global 
spread, has been reported2, 3, 4, 5, 6. The problem of resis-
tance, in addition to the absence of an effective vaccine 
for the control of the disease, require the search for 
new treatments. 
Currently, several studies have shown that molecules 
composed of two chemically linked structures, with 
two different pharmacophores and dual function, have 
become an important alternative for the treatment of 
diseases that share the problem of resistance. These 
molecules are called hybrids and potentiate the activ-
ity compared to the molecules used separately, in Plas-
modium strains resistant to them7, as is the case with 
ferroquine8 and some trioxaquine derivatives9.
In this work, we synthesized a hybrid by covalently 
binding Artesunate (artemisinin derivative) with Tu-
macona B (SN2) (Figure 1), a steroid isolated from 
plant S. nudum (HUA, Voucher 179201-Catalog of 
Colombian Flora). This steroid has antiplasmodial ac-
tivity (IC50 19,55 µM) in strain 7G8 CQ-resistant10  and 
its structure includes reactive hydroxyls moieties11,12, 
which allows the formation of a hybrid. Additionally, 
its A cycle has an a, b-unsaturated carbonyl group 
which has been related by studies of structure-activi-
ty relationship (SAR) with the promising antiplasmo-
dial activity of Diosgenone13, a natural compound also 
found in S. nudum. In our case, this a, b-unsaturated 
carbonyl group fulfills the role one of the two phar-
macophores for the hybrid’s formation. (See Figure 4 ) 
Compound 1. Artesunate (1)     Compound 2. Tumacona B 
                                                    (SN2) (2)
Figure 1. Chemical structures of molecular entities that 
formed the hybrid Artesunate-Tumacona B (3)
 
Compound 3. Arteether
Compound 4. Hybrid (ART-SN2) (3)   
Compound 5. Artemisinin         Compound 6. Diosgenone
Figure 2. Hybrid design based on antiplasmodial 
pharmacophores found in artemisinin (1, 2, 4-trioxanes) 
and sterols (a,b-unsaturated system in A ring). 
RESULTS AND DISCUSSION
CHEMISTRY
Synthesis of the hybrid Artesunate-Tumacona B 
(ART-SN2) 3 was developed in one step as shown in 
scheme 1, where the starting materials were Artesu-
nate (Sigma®) and pure Tumacona B (2) extracted from 
the plant S. nudum. Esterification between the carbox-
yl group of Artesunate and the two hydroxyl groups of 
Tumacona B was set in order to obtain two different 
hybrids (compounds 3 and 4) in which pharmacoph-
ores are held. To do this, the Yamaguchi-type esteri-
fication procedure was followed14 where compound 2, 
4, 6- trichlorobenzoyl chloride, known as Yamaguchi 
reagent, was coupled to Artesunate (1), which facilitat-
ed the primary alcohol nucleophilic attack (the most 
exposed and more reactive) of natural compound Tu-
macona B (2) for the formation of an ester-type hydro-
lyzable connector.
Compound 3 is hydrolyzable, so it becomes a dual 
prodrug and its individual molecules, after metabo-
lized, could be considered as the active substances. 
The expected compound 4 was not obtained, possibly 
due to steric hindrance in the region of the second-
ary hydroxyl of Tumacona B or the low reactivity this 
hydroxyl has with respect to the primary hydroxyl. 
However, we obtained compound 5, as an unexpected 
product resulting from the nucleophilic attack of the 
primary alcohol of Tumacona B to the Yamaguchi re-
agent acyl chloride, which is found in excess in the re-
action mixture. 
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Scheme 1. Synthesis of Artesunate - Tumacona B hybrid 
3. a.) THF at 0°C b) TEA, 2,4,6- trichlorobenzoyl chloride, 
rt, 2 h. (c) Tumacona B (2), DCM, DMAP, 24 h, rt.
Biological Assays
In vitro antiplasmodial assays were performed to 
hybrid 3 (SN2-ART and derivative 5 (SN2-YAM) in 
3D7 (chloroquine-sensitive) and FCR3 (chloroquine-
resistant) P. falciparum strains following the protocol 
adapted according to the methodologies described 
by Bravo and collaborators [15], and Desjardins and 
collaborators16. The same procedure was used to per-
form antiplasmodial assays a to molecules Tumacona 
B, Artesunate and its combination. In addition Mos-
mann method17 was followed to determine the cyto-
toxicity of compounds and the HepG2 cell line was 
employed.
In Table 1, we can observe that hybrid 3 (ART-SN2) 
showed an IC50 of 0.0059 µM for the FCR3 strain. 
For individual molecules in this same strain, an IC50 
of 0.0025 µM for Artesunate (1) and 60.6 µM for Tu-
macona B (SN2) was obtained. The hybrid 3 antiplas-
modial activity is in the same order of magnitude as 
the potent antimalarial Artesunate and is much bet-
ter than the natural starting compound Tumacona 
B (2). It is important to note that the IC50 of hybrid 
3, is approximately 23.4 times more potent than the 
one shown by chloroquine in resistant strains. Hy-
brid 3 was less toxic (12.6 µM) than Artesunate (1) 
(8.5 µM), exhibiting a SI of 2135.6, a high value that 
indicates its high selectivity for erythrocytes parasit-
ized with P. falciparum. This allows us to state that 
this compound has very low cytotoxicity.
Table 1. In vitro antiplasmodial activity and cytotoxicity 
of molecules obtained and of starting compounds. 
a IC50 (µM): Concentration corresponding to the 50% inhibi-
tion of parasite growth; b CC50 (µM): Concentration corres-
ponding to the 50% cytotoxic dose in HepG2 cells; c Selecti-
vity Index (SI) : HepG2 CC50 / FCR3 IC50; Antiplasmodial 
assay control. SD: standard deviation. FCR3: cloroquine 
resistant strain, 3D7: cloroquine sensitive strain.
Ester 5 (SN2-YAM) formed between SN2 and the 
Yamaguchi reagent presented an IC50 of 0.0445 µM 
in FCR3, and 0.041 µM in 3D7, showing that the de-
rivatization with the chlorinated compound dramati-
cally increased the antiplasmodial activity with respect 
to SN2 (IC50: 60.6 µM FCR3, 53.9 µM 3D7), resulting 
more potent than chloroquine. This IC50 exhibited by 
the derivative was 3 times higher than that of chloro-
quine. Despite the fact that compound 5 presented a 
higher cytotoxicity with a 3.87 µM CC50 in HepG2, the 
SI was 87, which tells us that this is a selective com-
pound towards the red blood cells parasitized with P. 
falciparum; that is, it shows very low cytotoxicity. 
The results from antiplasmodial activity in table 1 indi-
cate that the activity of hybrid 3 is greater than that of nat-
ural compound SN2; i.e., the covalent binding with Arte-
sunate (1) increases its individual antiplasmodial activity 
and favors the formation of a new artemisinin type deriva-
tive with an IC50 value of the same order as the Artesunate 
IC50. This result may become relevant in studies related 
to malaria episodes caused by parasites of P.falciparum 
artemisinin-resistant strains, since the hybrid could be a 
good alternative due to its potent activity, comparable to 
the Artemisinin derivatives currently used18. 
The antiplasmodial activity of combinations be-
tween the starting molecules can be calculated from 
the FICs (fractional inhibitory concentrations); this 
index allows us to know the effect of the interaction 
between two molecules. In table 2, FICs for strains 
3D7 and FCR3 were indifferent (3D7 FIC: 1.8; FCR3 
FIC: 1.58), indicating that the molecules in combina-
tion do not exert any effect (synergistic or antagonis-
tic) on each other, since it is established that a value 
between 0.51 to 4 is considered indifferent19. However, 
a molecule with an IC50 in the same order as Artesu-
nate is obtained when they are chemically linked.
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Table 2. Antiplasmodial activity of combinations of 
starting molecules.
aSD: Standard Deviation; bFICs: Fractional inhibitory con-
centrations; cART: Artesunate; dSN2: Tumacona B ; eIC10: 
Inhibitory concentration of 10% parasite growth.
IC10 SN2: 7.250 mM; IC10 ART: 2.0x10-3 mM
CONCLUSIONS
We obtained a promising Artesunate-Tumacona B hy-
brid (3) (ART- SN2) that exhibits potent antiplasmodial 
activity in vitro in chloroquine-sensitive and chloroquine 
-resistant strains, and also has a low cytotoxicity. This 
antiplasmodial activity was 23.4 times more potent than 
chloroquine for the resistant strain. The best therapeu-
tic option from the starting compounds is the formation 
of a hybrid because they do not potentiate between each 
other when are tested as a combination. (3D7 FIC: 1.8; 
FCR3 FIC: 1.58).
Although the hybrid displays the Artesunate phar-
macophore, this is a new molecule and it is possible to 
think that it has antiplasmodial effect in strains resistant 
to artemisinin, which could represent an alternative for 
artemisinin combination therapies. 
The derivative SN2-YAM (5), obtained from the esterifi-
cation reaction with the coupling reagent, showed greater 
activity and selectivity than the starting natural compound 
SN2; that is, a new compound was synthesized with inter-
esting physicochemical and biological characteristics.
The two compounds, obtained synthetically, are 
new and were analyzed by nuclear magnetic reso-
nance and mass analysis to verify their structure and 
molecular composition.
The results obtained in this study confirm the impor-
tance of hybrids as a therapeutic alternative for the treat-
ment of malaria and could be useful to guide future efforts 
to discover new antiplasmodial compounds of this type.
EXPERIMENTAL METHODS 
General information
We used Artesunate, 2, 4, 6-trichlorobenzoyl chlo-
ride (Yamaguchi reagent), triethylamine (TEA), 4-di-
methylaminopyridine (DMAP) and sodium borohy-
dride (SBH) from Sigma®; and tetrahydrofuran (THF) 
and Dichloromethane from Merck®. Methanol, hexane 
and ethyl acetate were commercial grade. The progress 
of the reactions was monitored by thin layer chroma-
tography (TLC), silica gel 60 F254 (Merck®). The plates 
were developed in a mix of acetic acid, sulfuric acid 
and water, as well as sublimated iodine and ultraviolet 
light. Chromatographic columns were made using a 
matrix of silica gel 60 (0.063-0.200 mm) Merck®. The 
IR spectrum was obtained in a 100 Spectrum (Perkin 
Elmer®) and the software used to interpret the results 
was the Spectrum v5.3.1. We utilized a Bruker® spec-
trometer for the spectroscopic analysis of 1H-NMR 
and 13C-NMR, 300 MHz for 1H and 75 MHz for 13C, 
using trimethylsilane as internal standard, and deu-
terated methanol (DME) and deuterated chloroform 
(DCCl3) from Merck® as solvents. The mass spectrum 
of hybrid 3 was obtained in a 6300 LC/MSD Trap SL 
mass spectrometer (Agilent Technologies®).
Procedure for the synthesis of the SN2-ART 
hybrid (3)
Hybrid 3 was synthesized from an esterification reaction 
via Yamaguchi. The following methodology was devel-
oped: 89.2 mg (0.23 mmol) of Artesunate 1 were diluted 
with 2.0 mL of THF, 0°C, then 57.5 µL of TEA and 54.4 
µL of Yamaguchi reagent (0.34 mmol) were added, then 
stirred in inert atmosphere and room temperature for two 
hours. Subsequently, 100 mg (0.23 mmol) of Tumacona 
B 2 and 44.25 mg (0.36 mmol) of DMAP were dissolved 
with 3.0 mL of DCM, which were slowly added to the 
solution and allowed to react for 24 hours (scheme 1). The 
reaction was stopped adding to the mixture a solution of 
distilled water saturated with ammonium chloride.
Two products were detected by TLC in the reaction 
mixture. Subsequently, a liquid–liquid extraction was 
performed using three washes of 15 mL of dichlo-
romethane. Then the organic phase was separated and 
concentrated to dryness and transferred to a chroma-
tographic column where separation and purification of 
compounds was obtained by gradient elution (hexane: 
ethyl acetate). Two white solids were obtained and iden-
tified after characterization as pure compounds 3 and 5. 
These are new compounds, obtained synthetically. Both 
the Artesunate-Tumacona B hybrid 3 and compound 5, a 
chlorinated derivative of Tumacona B, were analyzed by 
nuclear magnetic resonance and mass analysis to verify 
their structure and molecular composition.
Compound 3, white solid, showed a molecular ion 
[M+Na+] at m/z 819.6 (calculated for C46H68O11Na) in the 
spectrum of ESI-API-MS, corresponding to the molecu-
lar formula C46H68O11. Melting point (ºC): 176.34. IR (KBr, 
cm-1): 1735 (COOR), 1671 (C=O), 1014 (C-O), 3492 (C-
OH). The 1H NMR spectrum (300 MHz, DME) showed 
characteristic singlets attributed to three methyl groups 
d 0.826 (s, 3H), 1.245 (s, 3H), 1.368 (s, 3H), two doublets 
at d 0.87 (d, 3H, J: 9Hz), 1.189 (d, 3H, J:6 Hz), one triplet 
d 0.964 (t br, 6H, J: 9Hz, 3 Hz) and signal for one olefinic 
proton at d 5.530 (s, 1H); also one doublet is observed at 
d 5.772 (d, 1H, J: 9 Hz) and a markedly displaced singlet 
at d 5.730 (s,1H), belonging to the structural entity of Ar-
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tesunate and aliphatic protons between d 1,0 y 2,4, typical 
of a steroid skeleton. The 13C NMR spectrum (75MHz, 
DME) showed 46 signals, including the four carbonyls, 
one for a, b-unsaturated ketone at d 20.8, another for 
ketone at d 216.13 and signals for two esters at d 172.5 
and d 171.43. This demonstrates the covalent binding be-
tween Artesunate and the natural molecule Tumacona 
B (SN2). The rest of the chemical shifts for carbon were 
d:  173.57, 122.80, 103.73, 92.12, 91.14, 79.90, 75.25, 68.66, 
62.35, 53.77, 52.70, 51.57, 47.87, 45.18, 43.77, 39.45, 38.54, 
37.91, 36.90, 35.87, 35.67, 35.26, 34.85, 33.91, 33.28, 32.44, 
31.97, 31.84, 31.66, 28.67, 28.35, 26.67, 24.49, 24.40, 21.46, 
20.33, 19.18, 16.23, 15.89, 15.51, 12.41, 11.02. Compound 
3 was obtained in a 47% yield.
Compound 5 is a white solid with a molecular formu-
la C34H43Cl3O5, established by ESI-API-MS, showing 
a molecular ion [M+Na+] at m/z 659.3 (calculated for 
C34H43Cl3O5Na). Melting point (ºC): 172.5. IR (KBr, cm-
1): 1736 (COOR), 1670 (C=O), 1578 (C=C), 3422 (C-OH). 
The 1H NMR spectrum (300 MHz,  CDCl3) showed the 
characteristic singlets of the steroidal part attributed to 
methyl groups in d 0.78 (s, 3H) and d 1.21 (s, 3H), as well 
as d 5.63 corresponding to the olefinic proton of the a, b 
unsaturated system and one singlet at d 7.39 correspond-
ing to the two aromatic protons (s, 2H). One doublet is 
observed at d 1.05 (d, 4H, J: 6Hz). One triplet can also be 
observed in d 3.80 (t br, 1H, J: 3Hz) and one multiplet d 
4.27 (m, 2H, J: 4.27). There are also aliphatic protons be-
tween d 1.38 and 3.32 typical of the steroidal skeleton. The 
13C NMR spectrum (75MHz, CDCl3) showed 34 signals 
in total, including 3 carbonyls, one for a, b-unsaturated 
ketone at d 199.4 and one ester type in the region d 164.2, 
signal that suggests the binding between the entity of Ar-
tesunate and the Yamaguchi reagent (2,4,6-trichloroben-
zoyl chloride). The olefinic carbon was also observed at d 
171.0 and the hydroxylated secondary carbon, belonging 
to the structural entity of Tumacona B, at d 76.6. The 
other chemical shifts for carbon were d: 136.18, 132.57 
(2C), 128.08 (2C), 124.0, 70.78, 62.58, 53.48, 52.42, 48.63, 
44.09, 30.72, 38.77, 38.54, 35.62, 35.54, 34.97, 33.95, 32.79, 
32.08, 31.85, 27.09, 20.71, 17.33, 17.11, 17.06, 16.81, 13.75. 
Compound 5 was obtained in an 18% yield.
Biological Assays
In vitro antiplasmodial assays compounds 1, 2, 3, 5, 
were subjected to in vitro antiplasmodial activity assays in 
P. falciparum strains 3D7 (sensitive to chloroquine) and 
FCR3 (resistant to chloroquine) at 1% parasitemia and 2% 
hematocrit, following the protocol described by Bravo 
and collaborators in 1999 and Desjardins and collabora-
tors in 1979. The following concentrations were evaluated: 
1 (0.00098 to 0.065 µM), 2 (3.62 to 232 µM) 3 (0.00047 
to 0.031 µM) and 5 (0.0061 to 0.39µM), all dissolved in 
pure DMSO. Chloroquine was used as a positive control 
from 0.15 to 0.00234 μM for the sensitive strain and 2.0 
to 0.31 µM for the resistant strain, all dissolved in distilled 
water. All experiments were performed in triplicate, inde-
pendently, and the final concentration of the DMSO was 
always less than 0.1%. Antiplasmodial activity was done 
using radiolabeled hypoxanthine as follows: 96-well flat-
bottom plates, containing the concentrations to be evalu-
ated, were treated with 200uL of parasitized erythrocytes 
(1% parasitemia and 2% hematocrit) and 1 µC/mL of 3H-
hypoxanthine (MP Biomedicals, Santa Ana). The plates 
were incubated for 48 hours at 37°C in a 5% O2, 5% CO2 
atmosphere (balanced nitrogen). DNA of parasites was 
collected with the help of a semi-automatic harvester 
and radioactivity in µCi was measured on a scintillation 
counter (Merck®). An experiment was considered valid 
when reading of untreated control (culture media) wells 
was superior to 2000 cpm. Results were expressed as the 
average of the 50% inhibition concentration. Moreover, an 
IC50, for each compound, less than 1 µM20 was consid-
ered a promising activity or hit molecules, good from 1 to 
20µM21, moderate 20 to 100µM21, low activity 100 to 200 
µM21 and not active when greater than 200 µM21.
To determine the type of drug interaction between the 
Tumacona B (2) and Artesunate (1), we calculated the 
combination IC50 with a fixed concentration of Artesu-
nate in the case of Tumacona B (SN2), and a fixed concen-
tration of Tumacona B (SN2) in the case of Artesunate. 
The fixed concentration used was the IC10 of the maxi-
mum antiplasmodial effect. 
The combination IC50 values were employed to cal-
culate the fractional inhibitory concentrations (FICs) 
using equation 1. 
𝐹𝐹𝐹𝐹𝐹𝐹 = 𝐼𝐼𝐼𝐼 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐼𝐼 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝐴𝐴 𝐼𝐼𝐼𝐼50
𝑆𝑆𝑐𝑐𝐼𝐼𝐷𝐷𝑆𝑆𝑆𝑆 𝑑𝑑𝐷𝐷𝐷𝐷𝐷𝐷 𝐴𝐴 𝐼𝐼𝐼𝐼50 +  𝐼𝐼𝐼𝐼 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐼𝐼𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐼𝐼 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 𝐵𝐵 𝐼𝐼𝐼𝐼50𝑆𝑆𝑐𝑐𝐼𝐼𝐷𝐷𝑆𝑆𝑆𝑆 𝑑𝑑𝐷𝐷𝐷𝐷𝐷𝐷 𝐵𝐵 𝐼𝐼𝐼𝐼50       (1) 
 FICs: If the combination IC50 is less than that obtained 
with the single molecule, it is considered a synergistic 
effect (FIC < 0.5); if it is greater, anantagonistic (FIC > 4) 
or an indifferent effect when the FIC is (0.51 < FIC < 4). 
Cytotoxicity assays
Mosmann method17 was followed to determine the cy-
totoxicity of compounds. The HepG2 cell line was em-
ployed and cultivated in 96-well flat-bottom plates at a 
concentration of 2x105 cells/well in 100 µL of DMEM/
F12 medium supplemented with 10% fetal bovine se-
rum. The cells were incubated at 37°C with 5% CO2 for 
30 hours to allow monolayer formation. After that, 100 
μL of each compound was added to each well in serial 
concentrations as follows: 520.26 to 8.13µM for Artesu-
nate (1), 464.4 to 7.257µM for Tumacona B (2), 250.93 
to 3.92µM for compound 3 and 313.45 to 2.82µM for 
compound 5, and were solubilized in pure dimethyl 
sulfoxide. The plates were incubated for 48 hours at 
37°C. Afterwards, the MTT reagent was added and the 
absorbance of each well read at 595nm. The toxicity of 
Artesunate (1) in combination with Tumacona B (2) was 
evaluated using the CC10 of Artesunate (1) and different 
concentrations of Tumacona B (2) (464.4 to 7.257 µM). 
DMEM/F12 medium with 10% fetal bovine serum was 
employed as control of cell growth. The Tumacona B (2) 
and 2,4,6-trichlorobenzoyl chloride compounds could 
not be assessed in combination because chloride de-
composed immediately after it was added to the assay 
culture medium due to easy hydrolysis of acid chloride.
The toxicity of a molecule was considered according 
to the following ranges: CC50 <1.0 µg/mL (highly cyto-
toxic), 1.0-10.0 µg/mL (moderately cytotoxic), 10.0 -30.0 
µg/mL (medium toxicity) and >30 µg/mL (non-toxic) 22.
Regarding the selectivity index for classifying toxic 
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molecules, which is obtained from the ratio between 
the 50% toxic concentration (CC50) and the 50% an-
tiplasmodial concentration (IC50), it is considered a 
medium toxicity when this index is less than 1022.
Statistical analysis. A non-linear regression analy-
sis was performed to estimate the antiplasmodial ac-
tivity. These results correspond to means plus or mi-
nus standard deviations, which were obtained from 
three independent experiments. Statistical analyses 
were obtained in the Prism 5.0 (GraphPad) program.
A non-linear regression analysis was performed to 
estimate the cytotoxicity. The results correspond to 
means plus or minus standard deviations, obtained 
from two independent experiments. Statistical analyses 
were obtained in the Prism 5.0 (GraphPad) program.
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